CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms

References

• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951. doi: 10.1182/blood-2009-03-209262
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144–1148. doi: 10.1038/nature03546
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet. 2005;365:1054–1061. doi: 10.1016/S0140-6736(05)74230-6
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397. doi: 10.1016/j.ccr.2005.03.023
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790. doi: 10.1056/NEJMoa051113
   PubMed Web of Science ®Google Scholar
• Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788–22792. doi: 10.1074/jbc.C500138200
   PubMed Web of Science ®Google Scholar
• Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–468. doi: 10.1056/NEJMoa065202
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960–1963. doi: 10.1038/sj.leu.2404810
   PubMed Web of Science ®Google Scholar
• Scott LM, Beer PA, Bench AJ, et al. Prevalence of JAK2V617F and exon 12 mutations in polycythaemia vera. Br J Haematol. 2007;139:511–512. doi: 10.1111/j.1365-2141.2007.06806.x
   PubMed Web of Science ®Google Scholar
• Jones AV, Cross NC, White HE, et al. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica. 2008;93:1560–1564. doi: 10.3324/haematol.12883
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. doi: 10.1371/journal.pmed.0030270
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121:4388–4395. doi: 10.1182/blood-2013-02-486050
   PubMed Web of Science ®Google Scholar
• Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141–149. doi: 10.1182/blood-2008-01-131664
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–3476. doi: 10.1182/blood-2006-04-018879
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–2405. doi: 10.1056/NEJMoa1312542
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390. doi: 10.1056/NEJMoa1311347
   PubMed Web of Science ®Google Scholar
• Wang WA, Groenendyk J, Michalak M. Calreticulin signaling in health and disease. Int J Biochem Cell Biol. 2012;44(6):842–846. doi: 10.1016/j.biocel.2012.02.009
   PubMed Web of Science ®Google Scholar
• Jones A, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162–2168. doi: 10.1182/blood-2005-03-1320
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062–1069. doi: 10.1182/blood-2014-05-578435
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Rotunno G, Fanelli T, et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J. 2015;5:e360. doi: 10.1038/bcj.2015.90
   PubMed Web of Science ®Google Scholar
• Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431–438. doi: 10.1038/leu.2015.277
   PubMed Web of Science ®Google Scholar
• Li B, Xu J, Wang J, et al. Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica. 2014;99(11):1697–1700. doi: 10.3324/haematol.2014.109249
   PubMed Web of Science ®Google Scholar
• Qiao C, Sun C, Ouyang Y, et al. Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. Haematolgica. 2014;99:e182–e184. doi: 10.3324/haematol.2014.109199
   Web of Science ®Google Scholar
• Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–1551. doi: 10.1182/blood-2013-11-539098
   PubMed Web of Science ®Google Scholar
• Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014;28(12):2300–2303. doi: 10.1038/leu.2014.148
   PubMed Web of Science ®Google Scholar
• Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552–1555. doi: 10.1182/blood-2013-11-538983
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–1477. doi: 10.1038/leu.2014.3
   PubMed Web of Science ®Google Scholar